CytoDel, Inc., a privately-held corporation, today announces the publication of preclinical data on the company’s lead product, Cyto-111, in the peer-reviewed journal, Science Translational Medicine.
Roughly one in a hundred thousand people who received the Pfizer-BioNTech COVID-19 vaccine have had severe allergic reactions, US health officials said Wednesday while stressing that […]
In a Sounding Board article published in The New England Journal of Medicine, H. Gilbert Welch MD, MPH, Senior Investigator, Center for Surgery and Public Health, […]